Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr. Kazmi on Tailoring Treatment to Various Subtypes of CRC

March 19th 2021

Syed Kazmi, MD, discusses the importance of tailoring treatment to different subtypes of colorectal cancer.

Tilsotolimod/Ipilimumab Fails to Improve ORR in PD-1 Refractory, Advanced Melanoma

March 19th 2021

The combination of tilsotolimod plus ipilimumab failed to improve objective response rate over ipilimumab alone in patients with advanced melanoma who are refractory to a PD-1 inhibitor, missing the primary end point of the phase 2 ILLUMINATE-301 trial.

Dr. Eng on Extended RAS Analysis Results From the EPIC Trial in mCRC

March 17th 2021

Cathy Eng, MD, FACP, FASCO, discusses results from the extended RAS analysis of the phase 3 EPIC trial in patients with metastatic colorectal cancer.

Dr. Eng on the Potential of Trastuzumab Deruxtecan in HER2+ mCRC

March 16th 2021

Cathy Eng, MD, FACP, FASCO, discusses the potential of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive metastatic colorectal cancer.

Dr. Kazmi on Emerging Biomarkers in CRC

March 15th 2021

Syed Kazmi, MD, discusses emerging biomarkers that could help guide treatment decisions in patients with colorectal cancer.

Dr. Philip on Non-Operative Treatment Advances in CRC

March 12th 2021

Tony Philip, MD, discusses advances made in the treatment of patients with colorectal cancer.

GI Cancer Expert Is Searching for Big Leaps in Care

March 12th 2021

John L. Marshall, MD, has made it his mission to improve the lives of patients with GI cancers through innovative research, personalized medicine, and focused advocacy.

ctDNA, Total Neoadjuvant Therapy, and TAS-102 Signal a Shift in CRC Management

March 12th 2021

Tony Philip, MD, provides insight into the utility of ctDNA in the early-stage setting, trials that could determine its role in clinical practice, and detailed the shift toward nonoperative and less-intensive interventions in the early-stage and advanced settings, respectively.

Dr. Kazmi on Choosing Among Regorafenib and TAS-102 in Metastatic CRC

March 11th 2021

Syed Kazmi, MD, discusses choosing among regorafenib and TAS-102 in the treatment of patients with metastatic colorectal cancer.

ctDNA and Molecular Alterations Among Important Treatment Considerations in CRC

March 11th 2021

Atrayee Basu-Mallick, MD, discusses the emerging role of ctDNA as a predictive biomarker in early-stage CRC and the growing importance of molecular testing in the advanced-stage setting.

Dr. Basu-Mallick on Selecting Frontline HER2-Directed Therapy in CRC

March 10th 2021

Atrayee Basu-Mallick, MD, discusses factors to consider when selecting a frontline HER2-directed treatment regimen for patients with colorectal cancer.

Ciombor Cites Challenges in Optimizing Care for Locally Advanced Rectal Cancer

March 10th 2021

Determining the appropriate sequencing for chemotherapy and radiation in patients with locally advanced rectal cancer is important and may depend on whether the goal of therapy is nonoperative management.

Dr. Philip on the Emerging Role of ctDNA in CRC

March 9th 2021

Tony Philip, MD, discusses the emerging role of circulating tumor DNA in colorectal cancer.

Expert Panel Considers Clinical Scenarios With Data Gaps in GI Malignancies

March 8th 2021

Cathy Eng, MD, FACP, FASCO, and Jordan D. Berlin, MD discuss pressing questions in hepatocellular carcinoma, colorectal cancer, gastric cancer, neuroendocrine tumors, and pancreatic cancer.

Dr. Grothey on the Potential Utility of TAS-102/Bevacizumab in Metastatic CRC

March 8th 2021

Axel Grothey, MD, discusses the potential utility of trifluridine/tipiracil in combination with bevacizumab in metastatic colorectal cancer.

Dr. Basu-Mallick on Ongoing Research With ctDNA in CRC

March 5th 2021

Atrayee Basu-Mallick, MD, discusses the role of circulating tumor DNA in patients with colorectal cancer.

Dr. Bekaii-Saab on the Toxicity Differences Between Regorafenib and TAS-102 in CRC

March 4th 2021

Tanios S. Bekaii-Saab, MD, FACP, discusses the toxicity differences between regorafenib and trifluridine/tipiracil in colorectal cancer.

Dr. Philip on the Efficacy of TAS-102 in mCRC

March 4th 2021

Tony Philip, MD, discusses the efficacy of trifluridine/tipiracil in patients with metastatic colorectal cancer who are ineligible for intensive treatment.

Dr. Grothey on Dosing Strategies With Regorafenib in CRC

March 3rd 2021

Axel Grothey, MD, discusses dosing strategies with regorafenib in colorectal cancer.

Dr. Kazmi on Differences Between Left- Versus Right-Sided CRC Tumors

February 23rd 2021

Syed Kazmi, MD, discusses differences between left- and right-sided tumors in patients with colorectal cancer.